CardiAQ Gets $37.3M For Heart Valve Replacement
Irvine-based CardiAQ, which is developing medical devices used in percutaneous mitral heart valve replacement, said this morning that it has raised $37.3M in a Series B funding round. The funding was led by Orbimed, and also included Versant Ventures, Advent Life Sciences, and the firm's existing investors. CardiAQ said the funding will go towards validating its technology and towards feasibility and CE mark clinical trials. Orbimed's David Bonita and Vince Burgess join the company's board with the funding.
posted on Thursday, November 29, 2012 (Link to more information)

Related companies:

Related stories:
> CardiAQ Acquired By Edwards Lifesciences For $400M
> CardiAQ Sues Neovasc
> CoreValve Scores $33M
> CoreValve Acquired By Medtronic For $700M
> Arbor Surgical Pulls In $20M Home